Figure 3.

Mean change in Health Assessment Questionnaire disability index (HAQ DI) (A, B) and patient global assessment of disease activity (PtGA) (C, D) from baseline to week 256 by randomized treatment. Decreases from baseline in HAQ DI represent improvement and increases in PtGA indicate worsening disease activity (See Supplementary Table 1 available on the Arthritis Care & Research web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.22576/abstract for baseline HAQ DI and PtGA values). The placebo→golimumab 50 mg/100 mg group includes patients randomized to placebo who early escaped/crossed over at week 16/24 to receive golimumab 50 mg, with the possibility to increase golimumab from 50 to 100 mg after the week‐52 database lock. All patients could decrease the golimumab dose from 100 to 50 mg after the week‐52 database lock. The golimumab 50 mg/100 mg group includes patients randomized to receive golimumab 50 mg who early escaped at week 16 or dose escalated after the week‐52 database lock to receive golimumab 100 mg and also includes patients randomized to receive golimumab 100 mg. All patients could decrease the golimumab dose from 100 to 50 mg after the week‐52 database lock. MDA = minimal disease activity; ∗ = P < 0.005 vs. never achieved MDA; † = P < 0.0001 vs. never achieved MDA.